Formulation and evaluation of Cyclosporin A emulgel for ocular delivery

Abstract Emulgels have been extensively covered as a promising drug delivery system for the administration of lipophilic drugs. This work was conducted to develop an emulgel formulation for Cyclosporin A (CsA) employing polycarbophil as the gelling agent for ocular delivery. The prepared emulgels were evaluated for their physical appearance, rheological behavior, drug release, stability, precorneal clearance and irritation. Results showed that CsA emulgel formulations prepared with polycarbophil exhibited acceptable physical properties and drug release, which remained consistent after storage for 3 months. A prolonged retention time was also observed on the ocular surface with improved ocular bioavailability and no irritation. Therefore, the polycarbophil-based emulgel could be exploited as a potential hydrophobic drug carrier for topical ocular drug delivery.

[1]  V. Gupta,et al.  Formulation and evaluation of topical gel of diclofenac sodium using different polymers , 2015 .

[2]  Wei Wu,et al.  Ocular delivery of cyclosporine A based on glyceryl monooleate/poloxamer 407 liquid crystalline nanoparticles: preparation, characterization, in vitro corneal penetration and ocular irritation , 2012, Journal of drug targeting.

[3]  J. Veuthey,et al.  In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  Jinzhong Zhang,et al.  Safety of repeated topical ocular administration of a polycarbophil‐based formulation in several models of ocular surgery in rabbits , 2012, Journal of cataract and refractive surgery.

[5]  Mohammed A. Hammad,et al.  Novel Jojoba Oil-Based Emulsion Gel Formulations for Clotrimazole Delivery , 2011, AAPS PharmSciTech.

[6]  R. Gurny,et al.  Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  Tu Jia-sheng.  Study on Ophthalmic Emulsion-gel of Cyclosporine A , 2011 .

[8]  L. Kumar,et al.  In vitro evaluation of topical gel prepared using natural polymer , 2010 .

[9]  P. Surekha,et al.  Assessment of the dermal and ocular irritation potential of multi-walled carbon nanotubes by using in vitro and in vivo methods. , 2009, Toxicology letters.

[10]  C. Prestidge,et al.  The encapsulation and release of guanosine from PEGylated liposomes , 2009, Journal of liposome research.

[11]  S. Mazzitelli,et al.  Rheological and functional characterization of new antiinflammatory delivery systems designed for buccal administration. , 2008, International journal of pharmaceutics.

[12]  M. Mohamed.  Optimization of chlorphenesin emulgel formulation , 2004, The AAPS Journal.

[13]  María J Alonso,et al.  Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). , 2007, Biomaterials.

[14]  S. Kant,et al.  In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indomethacin. , 2003, Acta pharmaceutica.

[15]  R. Gurny,et al.  Cyclosporine A delivery to the eye: a pharmaceutical challenge. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  P. Ding,et al.  Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[17]  P. Costa,et al.  An alternative method to the evaluation of similarity factor in dissolution testing. , 2001, International journal of pharmaceutics.

[18]  B. Reis,et al.  Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial☆ , 2000 .

[19]  B. Reis,et al.  Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. , 2000, Ophthalmology.

[20]  H. Sucker,et al.  Oil-in water-emulsion gels: determination and mathematical treatment of flow properties. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[21]  L Timmermann,et al.  The mechanism of action of cyclosporin A and FK506. , 1996, Clinical immunology and immunopathology.

[22]  C. del Águila,et al.  Influence of Topically Applied Cyclosporine A in Olive Oil on Corneal Epithelium Permeability , 1994, Cornea.

[23]  A. Nordheim,et al.  Progress towards a molecular understanding of cyclosporin A-mediated immunosuppression , 1992, The clinical investigator.

[24]  M. Belin,et al.  Update on topical cyclosporin A. Background, immunology, and pharmacology. , 1990, Cornea.

[25]  T. Waaler,et al.  Rheological Characterization of Tear Substitutes , 1990 .

[26]  N. J. Van Haeringen,et al.  Clinical biochemistry of tears , 1981 .

[27]  N. V. van Haeringen.  Clinical biochemistry of tears. , 1981, Survey of ophthalmology.

[28]  E. L. Parrott,et al.  Pharmaceutical technology;: Fundamental pharmaceutics , 1970 .